Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 22;12(8):1999. doi: 10.3390/cancers12081999

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Targeting TLR4 signaling and proteasome activities resensitized to BTZ myeloma PCs cells from refractory patients. CD138+ cells obtained from refractory MM patients were treated with BTZ (5 nM) in combination or not with TAK-242 (10–20 µM). (A) The percentage of CD138+/annexin V+/7-ADD+ or CD138+/7ADD+ cells were estimated by flow cytometry 48 h post-treatment. (B) Mitochondrial membrane potential was assessed 24 h post-treatment analyzing MFI of DiOC2(3) staining on CD138+ cells by using flow cytometry. Bars indicate the standard error means. * p < 0.05; ** p < 0.01; *** p < 0.001.